We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
Cap. Flow
+$45.1M
Cap. Flow %
6.18%
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$40.8M
2
UTHR icon
United Therapeutics
UTHR
+$26.2M
3
HSKA
Heska Corp
HSKA
+$20M
4
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.2M
5
AZN icon
AstraZeneca
AZN
+$10.8M

Top Sells

Rank Stock Value
1
CCXI icon
ChemoCentryx, Inc.
CCXI
+$29.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$27.8M
3
DHR icon
Danaher
DHR
+$20.4M
4
APLS icon
Apellis Pharmaceuticals
APLS
+$15.4M
5
GSK icon
GSK
GSK
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Miscellaneous 16.98%
3 Communication Services 1.62%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
TARO icon
26
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$6.99M 0.96%
105,169
+28,710
+38% +$1.93M
2019 Q4
2 quarters
PCRX icon
27
Pacira BioSciences
PCRX
$1.45B
$6.96M 0.95%
+132,655
New +$5.54M
2020 Q2
0 quarters
MYOK
28
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.82M 0.94%
70,594
+42,842
+154% +$3.57M
2019 Q4
2 quarters
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$4.55M 0.62%
350,138
+177,945
+103% +$2.14M
2019 Q3
3 quarters
AFMD icon
30
DELISTED
Affimed
AFMD
$4.35M 0.6%
94,299
+38,219
+68% +$1.06M
2018 Q1
9 quarters
AMRX icon
31
Amneal Pharmaceuticals
AMRX
$6.65B
$4.22M 0.58%
+886,587
New +$3.65M
2020 Q2
0 quarters
AUTL icon
32
Autolus Therapeutics
AUTL
$426M
$4.14M 0.57%
258,360
+48,347
+23% +$536K
2020 Q1
1 quarter
MNTA
33
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.14M 0.57%
124,338
-22,212
-15% -$707K
2020 Q1
1 quarter
QGEN icon
34
Qiagen
QGEN
$9.51B
$3.53M 0.48%
+77,770
New +$3.48M
2020 Q2
0 quarters
CYTK icon
35
Cytokinetics
CYTK
$8.62B
$3.34M 0.46%
141,700
-40,000
-22% -$750K
2019 Q3
3 quarters
DRNA
36
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.27M 0.45%
128,905
+69,131
+116% +$1.49M
2018 Q2
8 quarters
RDUS icon
37
DELISTED
Radius Health, Inc.
RDUS
$3M 0.41%
220,110
-80,963
-27% -$1.11M
2017 Q4
10 quarters
HCA icon
38
HCA Healthcare
HCA
$98.7B
$2.95M 0.4%
30,400
-70,600
-70% -$7.34M
2020 Q1
1 quarter
VAPO
39
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$2.94M 0.4%
+8,977
New +$1.89M
2020 Q2
0 quarters
ALGN icon
40
PUT
Align Technology
ALGN
$10.5B
$2.74M 0.38%
10,000
– –
2020 Q1
1 quarter
DXCM icon
41
DexCom
DXCM
$32.4B
$2.7M 0.37%
26,680
-51,468
-66% -$4.6M
2019 Q3
3 quarters
BDSI
42
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.54M 0.35%
583,504
+460,802
+376% +$2.07M
2019 Q2
4 quarters
SNY icon
43
Sanofi
SNY
$96.4B
$2.54M 0.35%
49,778
-139,800
-74% -$6.79M
2017 Q4
10 quarters
CCXI icon
44
DELISTED
ChemoCentryx, Inc.
CCXI
$2.35M 0.32%
40,842
-539,169
-93% -$29.3M
2019 Q4
2 quarters
CNCE
45
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$2.32M 0.32%
+232,983
New +$2.23M
2020 Q2
0 quarters
PNTG icon
46
Pennant Group
PNTG
$1.45B
$2.32M 0.32%
102,568
-179,613
-64% -$3.76M
2019 Q4
2 quarters
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$2.18M 0.3%
601,163
+39,426
+7% +$103K
2019 Q1
5 quarters
KNSA icon
48
Kiniksa Pharmaceuticals
KNSA
$6.11B
$2.08M 0.29%
+81,700
New +$1.71M
2020 Q2
0 quarters
ALBO
49
DELISTED
Albireo Pharma Inc
ALBO
$2.07M 0.28%
78,029
– –
2018 Q1
9 quarters
LAB icon
50
Standard BioTools
LAB
$246M
$1.88M 0.26%
+467,923
New +$1.63M
2020 Q2
0 quarters
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.

  • Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
  • Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
  • Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
  • Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
  • Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
  • Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
  • Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.